TH07: the patented triple-combination drug candidate in Phase III development for androgenic alopecia

Our mission: to redefine the standard of care in hair loss

Androgenic alopecia has multiple biological causes, yet almost every treatment addresses only one. That is why results so often disappoint.

TH07 is different: a triple-combination, once-daily topical spray designed to target multiple growth pathways. It is now being evaluated in a randomized, placebo-controlled Phase III trial.

Explore the science

CLINICAL TRIAL

Now recruiting

Male participants for a Phase III clinical trial for androgenic alopecia

Triple Hair is now recruiting male patients for Phase III clinical trials for TH07, our investigational triple-combination product for androgenic alopecia, at participating clinical sites in Canada.

The trial is a triple-blind, randomized, placebo-controlled study running over 24 weeks. This milestone brings TH07 one step closer to potential approval for the millions of people affected by hair loss.

Check Eligibility

The Problem

Why monotherapies fall short

A disease with multiple causes, treated one cause at a time.

Androgenic alopecia is driven by multiple biological mechanisms at once. Most existing therapies address just one, so results fall short and many people give up on treatment. The problem was never the patient. It was the treatment.

Limited results, because single-agent treatments act on a single cause.
Hard to keep up, because greasy, twice-daily routines wear people down.
Systemic side effects of pill-based therapies
Millions still without a treatment that truly works.

Existing therapies: OnE pathway

Triple hair: Multiple pathways

Three pillars

Efficacy

Hair loss is caused by multiple growth pathways, and TH07 is designed to address them.

Safety

Scalp-targeted delivery, designed to keep the ingredients local to the scalp. Safety is being evaluated in the ongoing Phase III trial.

Compliance

A once-daily, non-greasy spray, designed to be easy to stay on.

THE HAIR LOSS MARKET

80 %

of men are affected
by androgenetic alopecia by age 70

Bhoyrul et al., Front Pharmacol 2026; Landells et al., J Cutan Med Surg 2025

$ 53.3 B

global alopecia market in 2025, projected to reach $100.6 billion by 2033; androgenetic alopecia accounts for 71% of it

Grand View Research, Alopecia Market Report, 2026

80 M

people in the United States are affected by androgenetic alopecia:
an estimated 50 million men and 30 million women

MedlinePlus, US National Library of Medicine, 2023

SOCIAL MEDIA

Latest insights and highlights

Insights from our research, milestones from our Phase 3 trial, and perspectives on why treating hair loss takes more than one pathway. See what the Triple Hair team is talking about.

See all posts

No LinkedIn posts found.

LEARN MORE

Learn more about TH07

Triple Hair is advancing TH07 through late-stage clinical development. To learn more, or to discuss investment and partnership, get in touch.

info@triplehair.ca